European Pharmaceutical Review

JUNE 24, 2022

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. This obviously presents a huge magnitude of risk for drug developers,” he noted.

Compounding 105

Compounding Drug Development Drug Pricing Dosage 105

pharmaphorum

JUNE 2, 2022

While in 2021, orphan drugs made up over half of all the US FDA’s approvals, with the figures in European being similarly high – 19 out of 54 approved new active substances. The report estimates that the orphan drug market will grow twice as fast as the non-orphan market, with a 2021 to 2026 compound annual growth rate of 12%.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 52

Safe Biologics

JUNE 12, 2023

Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. Unfortunately, the new drug-pricing rules enacted in the Inflation Reduction Act will stymie efforts to develop new cancer treatments.

Drug Pricing 100

Drug Pricing Drug Development Compounding 100

Safe Biologics

JUNE 12, 2023

Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. Unfortunately, the new drug-pricing rules enacted in the Inflation Reduction Act will stymie efforts to develop new cancer treatments.

Drug Pricing 100

Drug Pricing Drug Development Compounding 100

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 130

Biosimilars Drug Pricing Compounding Drug Development 130

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 100

Biosimilars Drug Pricing Compounding Drug Development 100

Pharmacy Times

JUNE 23, 2025

CMS is issuing unique J-codes for 505(b)(2) drugs, classifying them as sole-source products if not therapeutically equivalent. This pathway reduces submission denial risk, accelerates drug development, and offers potential market exclusivity for up to 7 years.

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Dosage Hospitals 26

pharmaphorum

AUGUST 27, 2020

Regulatory pressures, lengthy drug development times, and the fact that drug prices have become politicised have raised risks and cut revenue projections, leading to the biotech sector falling out of fashion.

Vaccines 122

Vaccines Drug Pricing Compounding Pharmaceutical Companies 122

STAT

MAY 8, 2025

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, we’ve got more news today about Vinay Prasad — let’s get into it. Read the rest…

Compounding Pharmacies 261

Compounding Pharmacies Compounding Drug Pricing Drug Development 261

STAT

DECEMBER 18, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, my colleagues were diligently roaming the halls of Congress yesterday, talking to senators about their thoughts on RFK Jr. Read on to hear what the lawmakers said. Read the rest…

Compounding 211

Compounding Drug Pricing Drug Development 211

STAT

JANUARY 6, 2025

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Today, we have a new biotech scorecard, which lays out the next quarter’s worth of the sector’s expected stock-moving events.

Compounding 282

Compounding Drug Pricing Drug Development 282

Drug Patent Watch

DECEMBER 19, 2024

Let’s explore the key components: Active Pharmaceutical Ingredients (APIs) Patents on APIs are the foundation of any drug patent portfolio. These protect the core molecule or compound that gives a drug its therapeutic effect. Q: What role does patent portfolio management play in drug pricing?

Pharmaceutical Companies 80

Pharmaceutical Companies Pharmaceutical Companies Dosage Drug Pricing 80

BioPharma Dive

JUNE 9, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Sponsored The golden era of GLP-1 drugs: How will it impact medicine and society? You can unsubscribe at anytime. Registered in England and Wales. TechTarget, Inc.s

Diabetes 59

Diabetes Drug Pricing Drug Development Compounding 59

Pharmaceutical Technology

JUNE 27, 2025

Compounded GLP-1RAs have completely disrupted pricing frameworks for Wegovy and Mounjaro, what happens now? Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 receptor agonists (GLP-1RA), due to the emergence of compounded alternatives in the past few years.

Drug Pricing 59

Drug Pricing Compounding Packaging Communication 59